Doxorubicin-SMCC is primarily utilized in the development of targeted cancer therapies. It serves as a key component in antibody-drug conjugates (ADCs), where the SMCC linker facilitates the attachment of doxorubicin, a potent chemotherapy agent, to monoclonal antibodies. These antibodies are designed to specifically recognize and bind to cancer cells, allowing for the precise delivery of the cytotoxic drug directly to the tumor site. This targeted approach minimizes damage to healthy tissues, reducing side effects commonly associated with traditional chemotherapy. Additionally, Doxorubicin-SMCC is employed in research to study drug delivery mechanisms and improve the efficacy of cancer treatments. Its application is particularly significant in treating cancers that are difficult to target with conventional methods.